Description: Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Home Page: www.verastem.com
117 Kendrick Street
Needham,
MA
02494
United States
Phone:
781 292 4200
Officers
| Name | Title |
|---|---|
| Mr. Brian M. Stuglik BPHARM, R.Ph., RPh | CEO & Director |
| Mr. Daniel W. Paterson | COO & Pres |
| Mr. Richard H. Aldrich M.B.A., Mba | Founder and Consultant |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board |
| Dr. Piyush B. Gupta Ph.D. | Co-Founder |
| Dr. Michelle Dipp M.D., Ph.D. | Co-Founder |
| Mr. Daniel Calkins | Interim Principal Accounting Officer & Financial Officer |
| Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer |
| Ms. Erin S. Cox | Sr. Director of Investor Relations & Corp. Communications |
| Mr. Sean C. Flynn | VP, Gen. Counsel & Sec. |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1394 |
| Price-to-Sales TTM: | 56.7822 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 48 |